Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF, Karagiannis SN. Josephs DH, et al. Among authors: koers a. Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17. Cancer Res. 2017. PMID: 28096174 Free PMC article.
AZD4625 is a Potent and Selective Inhibitor of KRASG12C.
Chakraborty A, Hanson L, Robinson D, Lewis H, Bickerton S, Davies M, Polanski R, Whiteley R, Koers A, Atkinson J, Baker T, Del Barco Barrantes I, Ciotta G, Kettle JG, Magiera L, Martins CP, Peter A, Wigmore E, Underwood Z, Cosulich S, Niedbala M, Ross S. Chakraborty A, et al. Among authors: koers a. Mol Cancer Ther. 2022 Oct 7;21(10):1535-1546. doi: 10.1158/1535-7163.MCT-22-0241. Mol Cancer Ther. 2022. PMID: 35930755 Free PMC article.
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, Keun HC, Chesler L. Yogev O, et al. Among authors: koers a. Cancer Res. 2016 May 15;76(10):3025-35. doi: 10.1158/0008-5472.CAN-15-1939. Epub 2016 Mar 29. Cancer Res. 2016. PMID: 27197232 Free article.
IgG4 subclass antibodies impair antitumor immunity in melanoma.
Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. Karagiannis P, et al. Among authors: koers a. J Clin Invest. 2013 Apr;123(4):1457-74. doi: 10.1172/JCI65579. J Clin Invest. 2013. PMID: 23454746 Free PMC article.
Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma.
Zormpas-Petridis K, Poon E, Clarke M, Jerome NP, Boult JKR, Blackledge MD, Carceller F, Koers A, Barone G, Pearson ADJ, Moreno L, Anderson J, Sebire N, McHugh K, Koh DM, Chesler L, Yuan Y, Robinson SP, Jamin Y. Zormpas-Petridis K, et al. Among authors: koers a. Cancer Res. 2020 Aug 15;80(16):3424-3435. doi: 10.1158/0008-5472.CAN-20-0133. Epub 2020 Jun 28. Cancer Res. 2020. PMID: 32595135
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.
Zormpas-Petridis K, Jerome NP, Blackledge MD, Carceller F, Poon E, Clarke M, McErlean CM, Barone G, Koers A, Vaidya SJ, Marshall LV, Pearson ADJ, Moreno L, Anderson J, Sebire N, McHugh K, Koh DM, Yuan Y, Chesler L, Robinson SP, Jamin Y. Zormpas-Petridis K, et al. Among authors: koers a. Cancer Res. 2019 Jun 1;79(11):2978-2991. doi: 10.1158/0008-5472.CAN-18-3412. Epub 2019 Mar 15. Cancer Res. 2019. PMID: 30877107 Free PMC article.
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.
Boult JKR, Apps JR, Hölsken A, Hutchinson JC, Carreno G, Danielson LS, Smith LM, Bäuerle T, Buslei R, Buchfelder M, Virasami AK, Koers A, Arthurs OJ, Jacques TS, Chesler L, Martinez-Barbera JP, Robinson SP. Boult JKR, et al. Among authors: koers a. Brain Pathol. 2018 Jul;28(4):475-483. doi: 10.1111/bpa.12525. Epub 2017 May 17. Brain Pathol. 2018. PMID: 28481062 Free PMC article.
SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Carreno G, Boult JKR, Apps J, Gonzalez-Meljem JM, Haston S, Guiho R, Stache C, Danielson LS, Koers A, Smith LM, Virasami A, Panousopoulos L, Buchfelder M, Jacques TS, Chesler L, Robinson SP, Martinez-Barbera JP. Carreno G, et al. Among authors: koers a. Endocr Relat Cancer. 2019 Mar;26(3):355-366. doi: 10.1530/ERC-18-0538. Endocr Relat Cancer. 2019. PMID: 30645190 Free PMC article.
28 results